Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors
Faeth Therapeutics appointed Adam Schayowitz, Ph.D., MBA, to its Board of Directors. He is EVP and Head of R&D at Zymeworks. He brings nearly 20 years of oncology drug development experience, including leadership roles at Pfizer Oncology and Tesaro, where he led development of Zejula.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.